Company intelligence / Profile preview
Moleac
Singapore, Singaporemoleac.com ↗
- Ownership
- Private
- Employees
- ~47
- Development stage
- Commercial
01
Overview
Moleac has successfully developed and commercialized NeuroAiD, an oral treatment for post-stroke recovery, and recently launched CognivAiD for vascular dementia which demonstrated significant and clinically meaningful disease-modifying benefits in clinical trials based on VaDAS-Cog and ADCS-CGIC scales with a favorable safety profile[1][5]
- Therapeutic areas
- Neurology
- Modalities
- Natural compoundsHerbal extracts
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Exclusive partnerships in over 30 countries[1]
Beyond the preview
Go deeper on Moleac.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Moleac.